Immune Checkpoint Inhibitors: Basics and Challenges

SHP-1: the next checkpoint target for cancer immunotherapy?

(2016) H. Angharad Watson et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Advances in immunotherapy for melanoma

(2016) Jason M. Redman et al.   BMC Medicine

Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity

(2016) Akiko Nagase-Zembutsu et al.   CANCER SCIENCE

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

Skin self-examination and long-term melanoma survival

(2016) Lisa E. Paddock et al.   MELANOMA RESEARCH

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PD-1 says goodbye, TIM-3 says hello

(2016) Diana Romero   Nature Reviews Clinical Oncology

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

(2016) Dickran Kazandjian et al.   ONCOLOGIST

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

(2016) R. D. Dorand et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

(2016) Susan P. Foy et al.   PLoS One

Excluding T Cells: Is β-Catenin the Full Story?

(2015) Siwen Hu-Lieskovan et al.   CANCER CELL

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

(2015) Nisha Nagarsheth et al.   CANCER RESEARCH

Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy

(2015) D. Di Mitri et al.   CLINICAL CANCER RESEARCH

Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study

(2015) P. Johnson et al.   CLINICAL CANCER RESEARCH

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma

(2015) Laurence Albiges et al.   EUROPEAN JOURNAL OF CANCER

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Refining the treatment of NSCLC according to histological and molecular subtypes

(2015) Anish Thomas et al.   Nature Reviews Clinical Oncology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

T-cell exhaustion in the tumor microenvironment

(2015) Y Jiang et al.   Cell Death & Disease

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity

(2015) Tong Seng Lim et al.   OncoImmunology

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

(2015) Margaret K. Callahan et al.   Frontiers in Oncology

Modulation of Immune Cell Functions by the E3 Ligase Cbl-b

(2015) Christina Lutz-Nicoladoni et al.   Frontiers in Oncology

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

(2015) Robert D. Leone et al.   Computational and Structural Biotechnology Journal

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

(2014) C. Lebbe et al.   ANNALS OF ONCOLOGY

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

(2014) Yanping Xiao et al.   JOURNAL OF EXPERIMENTAL MEDICINE

OX40- and CD27-Mediated Costimulation Synergizes with Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells To Exit Quiescence

(2014) Sarah L. Buchan et al.   JOURNAL OF IMMUNOLOGY

Acquired and intrinsic resistance in cancer immunotherapy

(2014) Sander Kelderman et al.   Molecular Oncology

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

(2014) Magdalena Paolino et al.   NATURE

Entering the mainstream of cancer treatment

(2014) Steven A. Rosenberg   Nature Reviews Clinical Oncology

Can we safely target the WNT pathway?

(2014) Michael Kahn   NATURE REVIEWS DRUG DISCOVERY

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune checkpoints in cancer clinical trials

(2014) Elad Sharon et al.   Chinese Journal of Cancer

Highlights of the Latest Advances in Research on CDK Inhibitors

(2014) Jonas Cicenas et al.   Cancers

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications

(2013) Juliano D. Paccez et al.   INTERNATIONAL JOURNAL OF CANCER

Treg and CTLA-4: Two intertwining pathways to immune tolerance

(2013) Lucy S.K. Walker   JOURNAL OF AUTOIMMUNITY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence

(2012) Tai-Wei Sun et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion

(2012) M. Platten et al.   CANCER RESEARCH

PD-1 is a novel regulator of human B-cell activation

(2012) Marie-Laure Thibult et al.   INTERNATIONAL IMMUNOLOGY

PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines

(2012) Bingbing Dai et al.   MOLECULAR THERAPY

The human microbiome: at the interface of health and disease

(2012) Ilseung Cho et al.   NATURE REVIEWS GENETICS

PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection

(2012) Sonia Norris et al.   VIRAL IMMUNOLOGY

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors

(2012) Aung Naing et al.   Journal of Cancer

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

(2011) Michael C. Schmid et al.   CANCER CELL

Prospects for TIM3-Targeted Antitumor Immunotherapy

(2011) S. F. Ngiow et al.   CANCER RESEARCH

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

(2011) E. J. Lipson et al.   CLINICAL CANCER RESEARCH

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

(2011) Zahra Hanaizi et al.   EUROPEAN JOURNAL OF CANCER

Mechanisms of drug resistance in kinases

(2011) Rina Barouch-Bentov et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Activation of the Canonical Wnt/β-Catenin Pathway in ATF3-Induced Mammary Tumors

(2011) Leqin Yan et al.   PLoS One

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epigenetic disruption of the WNT/ß-catenin signaling pathway in human cancers

(2010) Ying Ying et al.   Epigenetics

Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents

(2010) S. Kundu et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical importance of B7-H3 expression in human pancreatic cancer

(2009) I Yamato et al.   BRITISH JOURNAL OF CANCER

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

(2009) Kim Kramer et al.   JOURNAL OF NEURO-ONCOLOGY

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Selective expansion of a subset of exhausted CD8 T cells by  PD-L1 blockade

(2008) S. D. Blackburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA